Minimal Residual Disease Guides Postoperative Therapy in a Patient with ALK-rearrangement Adenocarcinoma: A Case Report

Technical Summary: Minimal Residual Disease Guides Postoperative Therapy in a Patient with ALK-rearrangement Adenocarcinoma

Problem Statement
Despite advances in targeted therapies for ALK-rearranged non-small cell lung cancer (NSCLC), predicting disease recurrence and determining the optimal duration of adjuvant therapy remain significant clinical challenges. While circulating tumor DNA (ctDNA)-based Minimal Residual Disease (MRD) monitoring has emerged as a promising tool for detecting molecular abnormalities undetectable by conventional imaging, its reliability in guiding treatment de-escalation—specifically the discontinuation of therapy in patients with negative MRD status—requires further validation. This case report addresses the critical question of whether negative MRD results can safely predict the absence of recurrence, particularly in the central nervous system (CNS), in patients with ALK-positive NSCLC.

Methodology
This study presents a retrospective case report of a 43-year-old female patient diagnosed with Stage IVA ALK-rearranged adenocarcinoma (cT1N2M1a). The clinical management followed a specific trajectory:

1. Initial Therapy: The patient received six months of targeted therapy with Alectinib (600 mg twice daily), achieving a partial response (PR).
2. Salvage Surgery: Following sustained PR, the patient underwent video-assisted thoracoscopic surgery (VATS) including right lower lobectomy and lymph node dissection. Postoperative pathology confirmed a complete response (pT0N0Mx).
3. Adjuvant Monitoring: The patient continued Alectinib for two years as adjuvant therapy. During this period, MRD status was monitored every six months via ctDNA analysis.
4. Therapy Discontinuation: After two years of treatment and three consecutive negative MRD tests, adjuvant Alectinib was discontinued.
5. Follow-up: The patient was monitored via Chest/Abdominal CT, Brain MRI, and Bone Scan. Two months after stopping therapy, clinical symptoms (dizziness) prompted re-evaluation.

Key Results

• Initial Success: The patient achieved a complete pathological response post-surgery and maintained negative MRD status for three consecutive monitoring intervals over two years.
• Recurrence Event: Two months after the discontinuation of Alectinib, the patient developed a new metastatic lesion (2.3 × 2.0 cm) in the occipital lobe of the brain.
• Diagnostic Discrepancy: At the time of recurrence, chest and abdominal CT scans showed no evidence of systemic tumor recurrence. The recurrence was detected solely through clinical symptoms and subsequent brain MRI, despite the preceding negative MRD results.
• Intervention: Targeted therapy with Alectinib was promptly re-initiated upon the discovery of the brain metastasis.

Key Contributions

• Clinical Evidence of Limitation: This case provides direct clinical evidence that ctDNA-based MRD monitoring, even when consistently negative, may fail to predict early CNS recurrence in ALK-positive NSCLC patients following the discontinuation of targeted therapy.
• Analysis of Detection Barriers: The authors identify specific technical and biological factors that may have contributed to the false-negative MRD result:
  • Blood-Brain Barrier: Peripheral blood samples may not accurately reflect intracranial MRD status due to the blood-brain barrier limiting ctDNA shedding from brain metastases.
  • Genetic Phenotypes: The specific genetic landscape of the tumor (e.g., ALK rearrangements) may influence ctDNA shedding rates compared to other mutations like TP53 or EGFR.
  • Technological Sensitivity: Current detection platforms (e.g., CAPP-Seq) have sensitivity limits (approx. 0.004% mutant allele frequency) and require prior knowledge of the tumor mutation profile, which may miss low-abundance residual clones.
• Cautionary Guidance: The report underscores that relying solely on MRD status to guide the de-escalation or cessation of adjuvant therapy in ALK-positive NSCLC is currently investigational and carries risks.

Significance and Claims
The paper claims that while MRD monitoring represents a significant advancement in NSCLC management, its current application in guiding treatment discontinuation is not yet fully validated. The authors emphasize that:

• MRD is not infallible: Negative MRD results do not guarantee the absence of residual disease, particularly in sanctuary sites like the brain.
• Need for Integration: Clinical decision-making should integrate MRD results with traditional imaging and pathological indicators rather than relying on MRD alone.
• Call for Further Research: The findings highlight the necessity for larger prospective studies to establish evidence-based protocols for MRD monitoring. Specifically, research is needed to validate the role of MRD in predicting CNS recurrence and to determine the optimal timing and strategy for de-escalating adjuvant therapy in ALK-positive patients.

The authors conclude that until such evidence is established, caution must be exercised when making therapeutic decisions based exclusively on MRD results.